Microparticles: Markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI

Kidney International

Volumn 87, Issue 6, 2015, Pages 1100-1108

  Souza, Ana Carolina P ^a   Yuen, Peter S T ^a   Star, Robert A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

biomarkers; coagulopathy; endothelial dysfunction; phosphatidylserine; thrombosis; tissue factor

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ANGIOGENESIS; BLOOD CLOTTING; CELL COMMUNICATION; CELL FUNCTION; CELLULAR SECRETION; CHRONIC KIDNEY DISEASE; COMORBIDITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; MEMBRANE MICROPARTICLE; MESENCHYMAL STEM CELL; MICROANGIOPATHY; MULTIPLE ORGAN FAILURE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; ACUTE KIDNEY INJURY; BLOOD; COMPLICATION; ENDOTHELIUM; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; VASCULAR DISEASES;

ACUTE KIDNEY INJURY; BIOMARKERS; CELL-DERIVED MICROPARTICLES; ENDOTHELIUM; HUMANS; IMMUNE TOLERANCE; MICROVESSELS; MULTIPLE ORGAN FAILURE; OXIDATIVE STRESS; SEPSIS; VASCULAR DISEASES;

EID: 84930276743     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.26     Document Type: Review

References (101)

1. Parmar A, Langenberg C, Wan L et al. Epidemiology of septic acute kidney injury. Curr Drug Targets 2009; 10: 1169-1178.
2. Ricci Z, Ronco C. Pathogenesis of acute kidney injury during sepsis. Curr Drug Targets 2009; 10: 1179-1183.
3. Yealy DM, Kellum JA, Huang DT et al. A randomized trial of protocolbased care for early septic shock. N Engl J Med 2014; 370: 1683-1693.
4. Finfer S, Bellomo R, Boyce N et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-2256.
5. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-941.
6. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebocontrolled trial of monoclonal antibody to human tumor necrosis factoralpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
7. Bernard GR, Francois B, Mira JP et al. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-alpha fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med 2014; 42: 504-511.
8. Burger D, Touyz RM. Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertension 2012; 6: 85-99.
9. Chawla LS, Eggers PW, Star RA et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371: 58-66.
10. Reid VL, Webster NR. Role of microparticles in sepsis. Brit J Anaesth 2012; 109: 503-513.
11. Lehr HA, Bittinger F, Kirkpatrick CJ. Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? J Pathol 2000; 190: 373-386.
12. Spronk PE, Zandstra DF, Ince C. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care 2004; 8: 462-468.
13. De Backer D, Donadello K, Favory R. Link between coagulation abnormalities and microcirculatory dysfunction in critically ill patients. Curr Opinion Anaesth 2009; 22: 150-154.
14. Sriskandan S, Altmann DM. The immunology of sepsis. J Pathol 2008; 214: 211-223.
15. Ince C, Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 1999; 27: 1369-1377.
16. Trzeciak S, Rivers EP. Clinical manifestations of disordered microcirculatory perfusion in severe sepsis. Crit Care 2005; 9(Suppl 4): S20-S26.
17. Ellis CG, Bateman RM, Sharpe MD et al. Effect of a maldistribution of microvascular blood flow on capillary O(2) extraction in sepsis. Am J Physiol Heart Circ Physiol 2002; 282: H156-H164.
18. Farquhar I, Martin CM, Lam C et al. Decreased capillary density in vivo in bowel mucosa of rats with normotensive sepsis. J Surg Res 1996; 61: 190-196.
19. Fries M, Weil MH, Sun S et al. Increases in tissue Pco2 during circulatory shock reflect selective decreases in capillary blood flow. Crit Care Med 2006; 34: 446-452.
20. Lam C, Tyml K, Martin C et al. Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 1994; 94: 2077-2083.
21. Wu L, Gokden N, Mayeux PR. Evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury. J Am Soc Nephrol 2007; 18: 1807-1815.
22. Holthoff JH, Wang Z, Patil NK et al. Rolipram improves renal perfusion and function during sepsis in the mouse. J Pharm Exp Ther 2013; 347: 357-364.
23. Mayeux PR, MacMillan-Crow LA. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsisinduced acute kidney injury. Pharmacol Ther 2012; 134: 139-155.
24. Verdant CL, De Backer D, Bruhn A et al. Evaluation of sublingual and gut mucosal microcirculation in sepsis: a quantitative analysis. Crit Care Med 2009; 37: 2875-2881.
25. De Backer D, Orbegozo Cortes D, Donadello K et al. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence 2014; 5: 73-79.
26. Meziani F, Delabranche X, Asfar P et al. Bench-to-bedside review: circulating microparticles-a new player in sepsis? Crit Care 2010; 14: 236.
27. Exline MC, Crouser ED. Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci 2008; 13: 5030-5041.
28. Lemasters JJ, Nieminen AL. Mitochondrial oxygen radical formation during reductive and oxidative stress to intact hepatocytes. Biosci Rep 1997; 17: 281-291.
29. Biesalski HK, McGregor GP. Antioxidant therapy in critical care-is the microcirculation the primary target? Crit Care Med 2007; 35(Suppl 9): S577-S583.
30. Holthoff JH, Wang Z, Seely KA et al. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 2012; 81: 370-378.
31. Wang Z, Holthoff JH, Seely KA et al. Development of oxidative stress in the peritubular capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute kidney injury. Am J Pathol 2012; 180: 505-516.
32. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157-171.
33. Pitanga TN, de Aragao Franca L, Rocha VC et al. Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells.. BMC Cell Biol 2014; 15: 21.
34. Burger D, Schock S, Thompson CS et al. Microparticles: biomarkers and beyond. Clin Sci (Lond) 2013; 124: 423-441.
35. Mortaza S, Martinez MC, Baron-Menguy C et al. Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. Crit Care Med 2009; 37: 2045-2050.
36. Zafrani L, Gerotziafas G, Byrnes C et al. Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release. Am J Resp Crit Care Med 2012; 185: 744-755.
37. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Gen 2012; 21: R125-R134.
38. Jansen F, Yang X, Hoyer FF et al. Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis. Arterioscler Thromb Vasc Biol 2012; 32: 1925-1935.
39. Dalli J, Norling LV, Renshaw D et al. Annexin 1 mediates the rapid antiinflammatory effects of neutrophil-derived microparticles. Blood 2008; 112: 2512-2519.
40. Ghosh A, Li W, Febbraio M et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008; 118: 1934-1943.
41. Leelahavanichkul A, Bocharov AV, Kurlander R et al. Class B scavenger receptor types I and II and CD36 targeting improves sepsis survival and acute outcomes in mice. J Immunol 2012; 188: 2749-2758.
42. Puddu P, Puddu GM, Cravero E et al. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010; 26: 140-145.
43. Mastronardi ML, Mostefai HA, Meziani F et al. Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011; 39: 1739-1748.
44. Nieuwland R, Berckmans RJ, McGregor S et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-935.
45. Wang JG, Manly D, Kirchhofer D et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemostasis 2009; 7: 1092-1098.
46. Woei AJFJ, van der Starre WE, Tesselaar ME et al. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res 2014; 133: 799-803.
47. Delabranche X, Boisrame-Helms J, Asfar P et al. Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Int Care Med 2013; 39: 1695-1703.
48. Zafrani L, Ince C, Yuen PS
49. Kapur NK, Morine KJ, Letarte M. Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Man 2013; 9: 195-206.
50. Woodfin A, Voisin MB, Nourshargh S. PECAM-1: a multi-functional molecule in inflammation and vascular biology. Art Thromb Vasc Biol 2007; 27: 2514-2523.
51. Montoro-Garcia S, Shantsila E, Marin F et al. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Bas Res Cardiol 2011; 106: 911-923.
52. Boomer JS, To K, Chang KC et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306: 2594-2605.
53. Chang KC, Burnham CA, Compton SM et al. Blockade of the negative costimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013; 17: R85.
54. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13: 862-874.
55. Venet F, Lukaszewicz AC, Payen D et al. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol 2013; 25: 477-483.
56. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Inf Dis 2013; 13: 260-268.
57. Sadallah S, Eken C, Martin PJ et al. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J Immunol 2011; 186: 6543-6552.
58. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leuk Biol 2013; 94: 247-257.
59. Marques FK, Campos FM, Sousa LP et al. Association of microparticles and preeclampsia. Mol Biol Rep 2013; 40: 4553-4559.
60. Knight M, Redman CW, Linton EA et al. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Brit J Ob Gyn 1998; 105: 632-640.
61. Arkwright PD, Rademacher TW, Boutignon F et al. Suppression of allogeneic reactivity in vitro by the syncytiotrophoblast membrane glycocalyx of the human term placenta is carbohydrate dependent. Glycobiol 1994; 4: 39-47.
62. Ling L, Huang H, Zhu L et al. Evaluation of plasma endothelial microparticles in pre-eclampsia. J Int Med Res 2014; 42: 42-51.
63. Rohde JM, Dimcheff DE, Blumberg N et al. Health care-associated infection after red blood cell transfusion: a systematic review and metaanalysis. JAMA 2014; 311: 1317-1326.
64. Carson JL. Blood transfusion and risk of infection: new convincing evidence. JAMA 2014; 311: 1293-1294.
65. Miyaji T, Hu X, Yuen PS et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int. 2003; 64: 1620-1631.
66. Souza AC, Volpini RA, Shimizu MH et al. Erythropoietin prevents sepsisrelated acute kidney injury in rats by inhibiting NF-kappaB and upregulating endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2012; 302: F1045-F1054.
67. Kao RL, Martin CM, Xenocostas A et al. Erythropoietin improves skeletal muscle microcirculation through the activation of eNOS in a mouse sepsis model. J Trauma. 2011; 71(5 Suppl 1): S462-S467.
68. Khan AI, Coldewey SM, Patel NS et al. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the betacommon receptor. Dis Models Mech 2013; 6: 1021-1030.
69. Coldewey SM, Khan AI, Kapoor A et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the beta-common receptor. Kidney Int 2013; 84: 482-490.
70. Nangaku M. Tissue protection by erythropoietin: new findings in a moving field. Kidney Int 2013; 84: 427-429.
71. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
72. Reinders ME, Sho M, Izawa A et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Inv 2003; 112: 1655-1665.
73. van der Flier M, van Leeuwen HJ, van Kessel KP et al. Plasma vascular endothelial growth factor in severe sepsis. Shock 2005; 23: 35-38.
74. Jeong SJ, Han SH, Kim CO et al. Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis. Crit Care 2013; 17: R97.
75. Yano K, Liaw PC, Mullington JM et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006; 203: 1447-1458.
76. Tsao PN, Chan FT, Wei SC et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med 2007; 35: 1955-1960.
77. Rafat N, Hanusch C, Brinkkoetter PT et al. Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med 2007; 35: 1677-1684.
78. Patschan SA, Patschan D, Temme J et al. Endothelial progenitor cells (EPC) in sepsis with acute renal dysfunction (ARD). Crit Care 2011; 15: R94.
79. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346.
80. Fan H, Goodwin AJ, Chang E et al. Endothelial progenitor cells and a stromal cell-derived factor-1alpha analogue synergistically improve survival in sepsis. Am J Resp Crit Care Med 2014; 189: 1509-1519.
81. Wang S, Aurora AB, Johnson BA et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-271.
82. Meng S, Cao JT, Zhang B et al. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol 2012; 53: 64-72.
83. Muramatsu F, Kidoya H, Naito H et al. microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin. Oncogene 2013; 32: 414-421.
84. Cantaluppi V, Gatti S, Medica D et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemiareperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int 2012; 82: 412-427.
85. Bitzer M, Ben-Dov IZ, Thum T. Microparticles and microRNAs of endothelial progenitor cells ameliorate acute kidney injury. Kidney Int 2012; 82: 375-377.
86. Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Med 2009; 15: 42-49.
87. Mostefai HA, Bourget JM, Meziani F et al. Interleukin-10 controls the protective effects of circulating microparticles from patients with septic shock on tissue-engineered vascular media. Clin Sci (Lond) 125: 77-85.
88. Gatti S, Bruno S, Deregibus MC et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusioninduced acute and chronic kidney injury. Nephrol Dial Transplant 2011; 26: 1474-1483.
89. Choi HY, Moon SJ, Ratliff BB et al. Microparticles from kidney-derived mesenchymal stem cells act as carriers of proangiogenic signals and contribute to recovery from acute kidney injury. PLoS One 2014; 9: e87853.
90. Lebiedz P, Knickel L, Engelbertz C et al. Impact of preexisting chronic kidney disease on acute and long-term outcome of critically ill patients on a medical intensive care unit. J Nephrol 2014; 27: 73-80.
91. Doi K, Leelahavanichkul A, Hu X et al. Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int 2008; 74: 1017-1025.
92. Leelahavanichkul A, Huang Y, Hu X et al. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int 2011; 80: 1198-1211.
93. McDonald HI, Thomas SL, Nitsch D. Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ Open 2014; 4: e004100.
94. Padberg JS, Wiesinger A, di Marco GS et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 2014; 234: 335-343.
95. Afsar B, Turkmen K, Covic A et al. An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014; 2014: 767424.
96. Jourde-Chiche N, Dou L, Cerini C et al. Vascular incompetence in dialysis patients-protein-bound uremic toxins and endothelial dysfunction. Sem Dial 2011; 24: 327-337.
97. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev 2013; 9: 331-339.
98. Faure V, Dou L, Sabatier F et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 2006; 4: 566-573.
99. Amabile N, Guerin AP, Leroyer A et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16: 3381-3388.
100. Dursun I, Poyrazoglu HM, Gunduz Z et al. The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2511-2518.
101. Rewa O, Bagshaw SM. Acute kidney injury-epidemiology, outcomes and economics. Nature Rev Nephrol 2014; 10: 193-207.